Compared side by side
Vesugen vs cardiogen: how they differ
The short answer
Both are short peptides from the Russian bioregulator program for the circulation: vesugen, three amino acids (Lys-Glu-Asp), is described as the bioregulator of the blood-vessel wall, and cardiogen, four (Ala-Glu-Asp-Arg), as the bioregulator of the heart. In lab cultures vesugen raised renewal markers in the cells that line blood vessels, and cardiogen made rat heart cells multiply; small Russian studies of vesugen with no placebo group report better blood flow, and no human study of cardiogen has been published. Both are run in short courses rather than continuously, and neither has a published dose in people.
Side by side
| Compared | Vesugen | Cardiogen |
|---|---|---|
| Category | Longevity | Longevity |
| Also known as | KED peptide, Lys-Glu-Asp, Vezugen | Ala-Glu-Asp-Arg, AEDR peptide |
| What it is | A short peptide from the Russian bioregulator program behind Epitalon and Pinealon, which its developers describe as a bioregulator for the blood-vessel wall. | A four-amino-acid peptide from the Russian bioregulator program, which its developers describe as a bioregulator for the heart. |
| How it works | A tripeptide, Lys-Glu-Asp (KED), from the Russian bioregulator program of Vladimir Khavinson's St. Petersburg Institute of Bioregulation and Gerontology, the group behind Epitalon and Pinealon. Its developers found it in their peptide extract of cattle blood vessels and describe it as the bioregulator of the vessel wall: in their scheme each short peptide regulates one tissue, by binding DNA and changing which genes are read. In cultures of the cells that line blood vessels it raised the markers of cell renewal and SIRT1 and brought endothelin-1, which rises in atherosclerosis, back toward normal; in mice bred to develop Alzheimer's disease, daily injections restored the stable "mushroom" spines where neurons connect. Its human data are a handful of small Russian studies with no placebo group. | A tetrapeptide, Ala-Glu-Asp-Arg (AEDR), from Vladimir Khavinson's St. Petersburg bioregulator program, which its developers describe as the bioregulator of the heart. In heart tissue from young and old rats grown in the lab it made cells multiply and lowered p53, a protein that drives cells toward death, and in old rats with a transplanted sarcoma it slowed the tumor through the tumor's blood vessels rather than by poisoning its cells. Its developers place it with Vesugen among the peptides that act on the aging signals of heart and vessel cells. No human study of Cardiogen is indexed on PubMed. |
| Commonly reported | User reports are few; those shared describe more stamina and stronger pumps in training over a few weeks. | Little to feel; user reports are few. |
| Studied range | No controlled study has set a dose of Vesugen: the amounts people run are their own protocol, not a reference. | No human study has tested a dose of Cardiogen: the amounts people run are their own protocol, not a reference. |
| How often | Daily | Daily |
| Half-life | Unknown (never measured) | Unknown (never measured) |
| Route | SubQ injection, Oral capsules | SubQ injection, Oral capsules |
| Typical run | Run in courses rather than continuously, like the other bioregulators. Its developers' capsules are labelled for a one-month course, repeated after 3–6 months; injected courses commonly run 10–20 days, a few times a year. No study has tested a course length. | Run in short courses rather than continuously, like the other bioregulators: community courses run about 10 days, a few times a year. No study in people has tested a course length. |
| Evidence | Emerging: primarily preclinical / limited human data | Emerging: primarily preclinical / limited human data |
| Common side effects | Injection-site sting or itch, mild stomach upset (capsules) | Injection-site redness or itch |
- Category
- VesugenLongevity
- CardiogenLongevity
- Also known as
- VesugenKED peptide, Lys-Glu-Asp, Vezugen
- CardiogenAla-Glu-Asp-Arg, AEDR peptide
- What it is
- VesugenA short peptide from the Russian bioregulator program behind Epitalon and Pinealon, which its developers describe as a bioregulator for the blood-vessel wall.
- CardiogenA four-amino-acid peptide from the Russian bioregulator program, which its developers describe as a bioregulator for the heart.
- How it works
- VesugenA tripeptide, Lys-Glu-Asp (KED), from the Russian bioregulator program of Vladimir Khavinson's St. Petersburg Institute of Bioregulation and Gerontology, the group behind Epitalon and Pinealon. Its developers found it in their peptide extract of cattle blood vessels and describe it as the bioregulator of the vessel wall: in their scheme each short peptide regulates one tissue, by binding DNA and changing which genes are read. In cultures of the cells that line blood vessels it raised the markers of cell renewal and SIRT1 and brought endothelin-1, which rises in atherosclerosis, back toward normal; in mice bred to develop Alzheimer's disease, daily injections restored the stable "mushroom" spines where neurons connect. Its human data are a handful of small Russian studies with no placebo group.
- CardiogenA tetrapeptide, Ala-Glu-Asp-Arg (AEDR), from Vladimir Khavinson's St. Petersburg bioregulator program, which its developers describe as the bioregulator of the heart. In heart tissue from young and old rats grown in the lab it made cells multiply and lowered p53, a protein that drives cells toward death, and in old rats with a transplanted sarcoma it slowed the tumor through the tumor's blood vessels rather than by poisoning its cells. Its developers place it with Vesugen among the peptides that act on the aging signals of heart and vessel cells. No human study of Cardiogen is indexed on PubMed.
- Commonly reported
- VesugenUser reports are few; those shared describe more stamina and stronger pumps in training over a few weeks.
- CardiogenLittle to feel; user reports are few.
- Studied range
- VesugenNo controlled study has set a dose of Vesugen: the amounts people run are their own protocol, not a reference.
- CardiogenNo human study has tested a dose of Cardiogen: the amounts people run are their own protocol, not a reference.
- How often
- VesugenDaily
- CardiogenDaily
- Half-life
- VesugenUnknown (never measured)
- CardiogenUnknown (never measured)
- Route
- VesugenSubQ injection, Oral capsules
- CardiogenSubQ injection, Oral capsules
- Typical run
- VesugenRun in courses rather than continuously, like the other bioregulators. Its developers' capsules are labelled for a one-month course, repeated after 3–6 months; injected courses commonly run 10–20 days, a few times a year. No study has tested a course length.
- CardiogenRun in short courses rather than continuously, like the other bioregulators: community courses run about 10 days, a few times a year. No study in people has tested a course length.
- Evidence
- VesugenEmerging: primarily preclinical / limited human data
- CardiogenEmerging: primarily preclinical / limited human data
- Common side effects
- VesugenInjection-site sting or itch, mild stomach upset (capsules)
- CardiogenInjection-site redness or itch
Typical run: Community practice — opinions vary. Not a clinical recommendation.

Week by week
Each entry’s cards by day window, as the compound pages show them. Day 1 is the day you start it.
Vesugen
- Day 1–14 Changes come over weeks
- Day 14–30 Where the studies measured blood flow
- Day 30–120 Courses spaced months apart
Cardiogen
- Day 1–10 Nothing in people to go on
- Day 10–60 What the rat heart tissue showed
Together or one or the other
Vesugen and cardiogen are a common stack: cardiogen lists vesugen among its common stacks.
Community · Cardiogen
The heart and vessel pair
Cardiogen is often run with Vesugen, the program's vessel peptide, one for the heart and one for the vessel wall. Its developers group the two together in their review of heart and vessel aging; no study has given them together.
Questions people ask
How long do vesugen and cardiogen last?
The half-life of vesugen is unknown (never measured). The half-life of cardiogen is unknown (never measured).
How often are vesugen and cardiogen taken?
Vesugen: daily. Routes: SubQ injection, oral capsules. Cardiogen: daily. Routes: SubQ injection, oral capsules.
How are vesugen and cardiogen dosed in research?
The library carries no reference dose for vesugen. No controlled study has set a dose of Vesugen: the amounts people run are their own protocol, not a reference. The library carries no reference dose for cardiogen. No human study has tested a dose of Cardiogen: the amounts people run are their own protocol, not a reference.
What are the common side effects of vesugen and cardiogen?
For vesugen, the library lists: injection-site sting or itch, mild stomach upset (capsules). For cardiogen: injection-site redness or itch.
Are vesugen and cardiogen taken together?
Vesugen and cardiogen are a common stack: cardiogen lists vesugen among its common stacks. Cardiogen is often run with Vesugen, the program's vessel peptide, one for the heart and one for the vessel wall. Its developers group the two together in their review of heart and vessel aging; no study has given them together.